Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

ABSTRACT:

Importance

The association of bullous pemphigoid (BP) with the use of dipeptidyl-peptidase 4 (DPP-4) inhibitors among patients with diabetes has recently emerged. The risk of developing BP during treatment with new DPP-4 inhibitor agents like linagliptin is yet to be established. The clinical features and the prognostic outcomes of patients with DPP-4 inhibitor-associated BP are yet to be established.

Objectives

Primarily to estimate the association between DPP-4 inhibitor exposure and the development of BP, and secondarily to characterize the clinical features and history of patients with DPP-4 inhibitor-associated BP.

Design, setting, and participants

A retrospective case-control study of the intake of different DPP-4 inhibitor agents and metformin and occurrence of

SUBMITTER: Kridin K 

PROVIDER: S-EPMC6233738 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature